Search - tctmd.com

Displaying 441 - 458 of 458

Sort: Relevancy | Date

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Industry News

Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

September 29, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Daily News

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

L.A. McKeown

September 13, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Conference News

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

August 28, 2011

News Daily News

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Caitlin E. Cox

August 10, 2011

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

News Daily News

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

Jason Kahn

February 13, 2011

News Daily News

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Jason Kahn

February 09, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

January 04, 2011

News Industry News

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

January 04, 2011

Video

» Topical Discussion

Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk

June 27, 2022

Advertisement

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Hope Renewed for Novel Anticoagulant Use in ACS

Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Prothrombin Works as Antidote to Rivaroxaban, Not Dabigatran

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

ESC Congress 2011: Drugs, Devices Work Together

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Bests Warfarin in Stroke Prevention for Atrial Fib

ROCKET AF Published: Rivaroxaban Matches Warfarin in Treating A-Fib Patients

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Dabigatran Recommended as Alternative to Warfarin in A-fib Patients

New Anticoagulant More Effective Than Aspirin at Stroke Prevention in A-fib

Bayer’s Rivaroxaban Submitted for Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation in the US

Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis

Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content